Esophageal Cancer Therapeutics - Pipeline Assessment and Market Forecast to 2017

GlobalData, July 2011, Pages: 92

Esophageal Cancer Therapeutics - Pipeline Assessment and Market Forecast to 2017

Summary

GlobalData, the industry analysis specialist, has released its new report, “Esophageal Cancer Therapeutics - Pipeline Assessment and Market Forecast to 2017”. The report is an essential source of information and analysis on the global Esophageal Cancer Therapeutics market. The report identifies the key trends shaping and driving the global Esophageal Cancer Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Esophageal Cancer Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Scope

The report provides information on the key drivers and challenges of the Esophageal Cancer Therapeutics market. Its scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Esophageal Cancer Therapeutics market revenues data from 2005 to 2009, forecast for eight years to 2017.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
- Analysis of the current and future competition in the seven key countries Esophageal Cancer Therapeutics market.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Esophageal Cancer Therapeutics therapeutics market.
- Analysis of key recent licensing and partnership agreements in Esophageal Cancer Therapeutics market

Reasons to buy

The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global Esophageal Cancer Therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Esophageal Cancer Therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global Esophageal Cancer Therapeutics market landscape? – Identify, understand and capitalize.

1
1

1.1 List of Tables
1.2 List of Figures
2 Esophageal Cancer Therapeutics: Introduction
2.1 Disease Overview
2.2 Epidemiology
2.3 Risk Factors
2.4 Etiology
2.5 Symptoms
2.6 Diagnosis
2.7 Staging
2.8 Survival Rate by Stage
2.9 Treatment and Management Pattern
2.9.1 Treatment Algorithm for Esophageal Cancer
2.9.2 Surgery
2.9.3 Radiation Therapy
2.9.4 Targeted Drug Therapy and Chemotherapy
2.9.5 Chemotherapy Regimens
2.9.6 Chemoradiation Regimens
2.9.7 Laser Therapy
2.9.8 Electrocoagulation
2.9.9 Photodynamic Therapy
2.10 Pipeline Report Guidance
3 Esophageal Cancer Therapeutics: Market Characterization
3.1 Esophageal Cancer Therapeutics Market Size (2005-2010) – Global
3.2 Esophageal Cancer Therapeutics Market Forecast (2010-2017) – Global
3.3 Esophageal Cancer Therapeutics Market Size (2005-2010) – The US
3.4 Esophageal Cancer Therapeutics Market Forecast (2010-2017) – the US
3.5 Esophageal Cancer Therapeutics Market Size (2005-2010) – the UK
3.6 Esophageal Cancer Therapeutics Market Forecast (2010-2017) –UK
3.7 Esophageal Cancer Therapeutics Market Size (2005-2010) – France
3.8 Esophageal Cancer Therapeutics Market Forecast (2010-2017) – France
3.9 Esophageal Cancer Therapeutics Market Size (2005-2010) – Germany
3.10 Esophageal Cancer Therapeutics Market Forecast (2010-2017) – Germany
3.11 Esophageal Cancer Therapeutics Market Size (2005-2010) – Italy
3.12 Esophageal Cancer Therapeutics Market Forecast (2010-2017) – Italy
3.13 Esophageal Cancer Therapeutics Market Size (2005-2010) – Spain
3.14 Esophageal Cancer Therapeutics Market Forecast (2010-2017) – Spain
3.15 Esophageal Cancer Therapeutics Market Size (2005-2010) – Japan
3.16 Esophageal Cancer Therapeutics Market Forecast (2010-2017) – Japan
3.17 Drivers and Barriers for Esophageal Cancer
3.17.1 Drivers for the Esophageal Cancer Therapeutics
3.17.2 Barriers for the Esophageal Cancer Therapeutics
3.18 Opportunity and Unmet Needs
3.19 Key Takeaway
4 Esophageal Cancer Therapeutics Market: Competitive Assessment
4.1 Overview
4.1.1 Strategic Competitor Assessment
4.2 Product Profiles for the Major Product and Regimens in Esophageal Cancer
4.2.1 Targeted Drugs
4.2.2 Chemotherapy Regimens
4.3 Key Takeaway
5 Esophageal Cancer Therapeutics: Pipeline Assessment
5.1 Overview
5.2 Strategic Pipeline Assessment
5.3 Pipeline Analysis by Phase of Development
5.3.1 Esophageal Cancer Therapeutics – Phase III Clinical Pipeline
5.3.2 Esophageal Cancer Therapeutics – Phase II Clinical Pipeline
5.3.3 Esophageal Cancer Therapeutics – Phase I Clinical Pipeline
5.3.4 Esophageal Cancer Therapeutics – Discovery Clinical Pipeline
5.4 Esophageal Cancer Therapeutics – Clinical Pipeline by Mechanism of Action
5.5 Esophageal Cancer Therapeutics – Other Promising Mechanisms of Actions
5.6 Technology Trends Analytic Framework
5.7 Esophageal Cancer Therapeutics – Promising Drugs in Clinical Development
5.8 Molecule Profile for Promising Drugs under Clinical Development
5.8.1 Avastin (bevacizumab)
5.8.2 Erbitux (cetuximab)
5.8.3 Ramucirumab (IMC-1121B)
5.8.4 Tykerb (lapitinib)
5.9 Key Takeaway
6 Esophageal Cancer Therapeutics: Clinical Trials Mapping
6.1 Clinical Trials by Country (US, EU5 and Japan)
6.2 Clinical Trials by Phase
6.3 Clinical Trials by Trial Status
6.4 Prominent Sponsors
6.5 Top Companies Participating in Esophageal Cancer Therapeutics Clinical Trials
7 Esophageal Cancer Therapeutics: Strategic Assessment
7.1 Key Events Impacting the Future Market
7.2 Future Market Competition Scenario
8 Esophageal Cancer Therapeutics: Future Players
8.1 Introduction
8.2 Company Profiles for the Promising and Marketed Drugs
8.2.1 Merck KGaA
8.2.2 Eli-Lilly and Co. Ltd.
8.2.3 F. Hoffmann-La Roche/Genentech
8.2.4 Glaxosmithkline PLC
8.3 Other Companies in the Esophageal Cancer Market, 2011
9 Esophageal Cancer Therapeutics: Licensing and Partnership Deals
10 Esophageal Cancer Therapeutics: Appendix
10.1 Market Definitions
10.2 Abbreviations
10.3 Methodology
10.3.1 Coverage
10.3.2 Secondary Research
10.3.3 Forecasting
10.3.4 Primary Research
10.3.5 Expert Panel Validation
10.4 Contact Us
10.5 Disclaimer
10.6 Bibliography

1.1 List of Tables
Table 1: Incidence and Mortality for Esophageal Cancer in Seven Major Markets, 2010
Table 2: Survival Rates by Staging, 2010
Table 3: Perioperative Chemotherapy Regimens
Table 4: First Line Chemotherapy Regimens
Table 5: Second Line Chemotherapy Regimens
Table 6: Alternative Chemotherapy Regimens
Table 7: Preoperative Chemoradiation Regimens
Table 8: Postoperative Chemoradiation Regimens
Table 9: Definitive Chemoradiation Regimens
Table 10: Esophageal Cancer Therapeutics Market, Global, Revenue ($m), 2005-2010
Table 11: Esophageal Cancer Therapeutics Market, Global, Market Forecast ($m), 2010-2017
Table 12: Esophageal Cancer Therapeutics Market, The US, Revenue ($m), 2005-2010
Table 13:Esophageal Cancer Therapeutics Market, the US, Market Forecast ($m), 2010-2017
Table 14: Esophageal Cancer Therapeutics Market, the UK, Revenue ($m), 2005-2010
Table 15:Esophageal Cancer Therapeutics Market, UK, Market Forecast ($m), 2010-2017
Table 16: Esophageal Cancer Therapeutics Market, France, Revenue ($m), 2005-2010
Table 17:Esophageal Cancer Therapeutics Market, France, Market Forecast ($m), 2010-2017
Table 18: Esophageal Cancer Therapeutics Market, Germany, Revenue ($m), 2005-2010
Table 19:Esophageal Cancer Therapeutics Market,Germany, Market Forecast ($m),2010-2017
Table 20:Esophageal Cancer Therapeutics Market, Italy, Revenue ($m), 2005-2010
Table 21:Esophageal Cancer Therapeutics Market, Italy, Market Forecast ($m), 2010-2017
Table 22: Esophageal Cancer Therapeutics Market, Spain, Revenue ($m), 2005-2010
Table 23: Esophageal Cancer Therapeutics Market, Spain, Market Forecast ($m), 2010-2017
Table 24:Esophageal Cancer Therapeutics Market, Japan, Revenue ($m), 2005-2010
Table 25: Esophageal Cancer Therapeutics Market, Japan, Market Forecast ($m), 2010-2017
Table 26: Esophageal Cancer Therapeutics – Phase III Clinical Pipeline, 2011
Table 27: Esophageal Cancer Therapeutics – Phase II Clinical Pipeline, 2011
Table 28: Esophageal Cancer Therapeutics – Phase I Clinical Pipeline, 2011
Table 29: Esophageal Cancer Therapeutics – Discovery Clinical Pipeline, 2011
Table 30: Esophageal Cancer Therapeutics – Other Promising Mechanisms of Actions
Table 31: Esophageal Cancer Therapeutics – Promising Drugs in Clinical Development
Table 32: Esophageal Cancer Therapeutics – Clinical Trials by Region/Country, 2011
Table 33: Esophageal Cancer Therapeutics – Clinical Trials by Phase, 2011
Table 34: Esophageal Cancer Therapeutics – Clinical Trials by Trial Status, 2011
Table 35: Esophageal Cancer Therapeutics – Clinical Trials by Overall Sponsors, 2011
Table 36: Esophageal Cancer Therapeutics – Clinical Trials by Prominent Sponsors, 2011
Table 37: Esophageal Cancer Therapeutics – Clinical Trials by Top Companies, 2011
Table 38: Merck KGaA – Oncology Pipeline Products, 2011
Table 39: Merck KGaA – Esophageal Cancer Pipeline Product, 2011
Table 40: Merck KGaA – Deals
Table 41: Eli-Lilly and Co. Ltd – Oncology Pipeline Products, 2011
Table 42: Eli-Lilly and Co. Ltd – Esophageal Cancer Pipeline Product, 2011
Table 43: Eli-Lilly and Co. Ltd – Deals
Table 44: F. Hoffmann-La Roche – Oncology Pipeline Products, 2011
Table 45: F. Hoffmann-La Roche – Esophageal Cancer Pipeline Products, 2011
Table 46: F. Hoffmann-La Roche – Deals
Table 47: Glaxosmithkline – Esophageal Cancer Pipeline Product, 2011
Table 48: Glaxosmithkline – Esophageal Cancer Pipeline Product, 2011
Table 49: Glaxosmithkline PLC – Deals
Table 50: Esophageal Cancer Therapeutics – Future Players, 2011
Table 51: Esophageal Cancer Therapeutics, Global, Deals

1.2 List of Figures
Figure 1: Risk Factors for Two Types of Esophageal Cancer
Figure 2: TNM Classification of Carcinoma of the Esophagus
Figure 3: TNM Staging Of Squamous Cell Carcinoma
Figure 4: TNM Staging of Adenocarcinoma or GE Junction Adenocarcinoma
Figure 5: Treatment Algorithm of Esophageal Cancer, 2010
Figure 6: Esophageal Cancer Therapeutics Market, Global, Revenue ($m), 2005-2010
Figure 7: Esophageal Cancer Therapeutics Market, Global, Market Forecast ($m), 2010-2017
Figure 8: Esophageal Cancer Therapeutics Market, the US, Revenue ($m), 2005-2010
Figure 9: Esophageal Cancer Therapeutics Market, the US, Market Forecast ($m), 2010-2017
Figure 10: Esophageal Cancer Therapeutics Market, the UK, Revenue ($m), 2005-2010
Figure 11: Esophageal Cancer Therapeutics Market, UK, Market Forecast ($m), 2010-2017
Figure 12: Esophageal Cancer Therapeutics Market, France, Revenue ($m), 2005-2010
Figure 13: Esophageal Cancer Therapeutics Market, France, Market Forecast ($m), 2010-2017
Figure 14: Esophageal Cancer Therapeutics Market, Germany, Revenue ($m), 2005-2010
Figure 15: Esophageal Cancer Therapeutics Market, Germany, Market Forecast ($m), 2010-2017
Figure 16: Esophageal Cancer Therapeutics Market, Italy, Revenue ($m), 2005-2010
Figure 17: Esophageal Cancer Therapeutics Market, Italy, Market Forecast ($m), 2010-2017
Figure 18: Esophageal Cancer Therapeutics Market, Spain, Revenue ($m), 2005-2010
Figure 19: Esophageal Cancer Therapeutics Market, Spain, Market Forecast ($m), 2010-2017
Figure 20: Esophageal Cancer Therapeutics Market, Japan, Revenue ($m), 2005-2010
Figure 21: Esophageal Cancer Therapeutics Market, Japan, Market Forecast ($m), 2010-2017
Figure 22: Opportunity and Unmet Need in the Esophageal Cancer Therapeutics Market, 2010
Figure 23: Esophageal Cancer Therapeutics Pipeline by Phase of Clinical Development, 2011
Figure 24: Esophageal Cancer Therapeutics – Clinical Pipeline by Mechanism of Action, 2011
Figure 25: Technology Trends Analytic Framework of the Esophageal Cancer Therapeutics Pipeline, 2011
Figure 26: Technology Trends Analytic Framework of the Esophageal Cancer Therapeutics Pipeline – Description, 2011
Figure 27: Esophageal Cancer Therapeutics – Clinical Trials by Country, 2011
Figure 28: Esophageal Cancer Therapeutics – Clinical Trials by Phase, 2011
Figure 29: Esophageal Cancer Therapeutics – Clinical Trials by Trial Status, 2011
Figure 30: Esophageal Cancer Therapeutics – Clinical Trials by Overall Sponsors, 2011
Figure 31: Esophageal Cancer Therapeutics – Clinical Trials by Prominent Sponsors, 2011
Figure 32: Esophageal Cancer Therapeutics – Clinical Trials by Top Companies, 2011
Figure 33: Esophageal Cancer Therapeutics – Drivers and Barriers, 2010
Figure 34: Esophageal cancer Therapeutics – Implications for Future Market Competition, 2010
Figure 35: Esophageal Cancer Therapeutics – Pipeline by Company, 2011
Figure 36: Market Forecasting Model

Merck KGaA
Eli-Lilly and Co. Ltd.
F. Hoffmann-La Roche/Genentech
Glaxosmithkline PLC

Customers who bought this item also bought

• Global Esophageal Cancer Epidemiology and Patient Flow Analysis - 2012
• Esophageal Achalasia Global Clinical Trials Review, H1, 2012
• Esophageal Achalasia Global Clinical Trials Review, H1, 2013
• Global Gastrointestinal Disorders Drug Pipeline Capsule - 2012
• Esophageal Diseases - Pipeline Review, H2 2012
• Global Pancreatic Cancer Epidemiology and Patient Flow Analysis - 2012
• Global Prostate Cancer Epidemiology and Patient Flow Analysis - 2012
• Personalized Medicine - Scientific and Commercial Aspects
• Oncology Partnering Terms and Agreements
• RNA Interference (RNAi) - Global Strategic Business Report